Sprycel (dasatinib) developed by New York-based Bristol-Myers Squibb is an oral inhibitor of multiple tyrosine kinases, for the treatment of adults in all phases of chronic myeloid leukemia with resistance or intolerance to prior therapy, including Gleevec (imatinib mesylate). The success of Sprycel is based on hematologic and cytogenetic response rates. There are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased endurance. The...
| Currently you cannot purchase Sprycel as it might be not available for sale online or on local pharmacy. Subscribe below and we will inform you where and when you can order Sprycel |
| Sprycel Availability Subscription Form |
|
| |
| Note: We will email you when Sprycel is available for sale online or in pharmacy in your country. |
|
|
|
|
